Millstone Evans Group’s AbbVie ABBV Stock Holding History

Millstone Evans Group’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$629K	Sell	2,498 -585	-19%	-$126K	0.34%	51
2026 Q1	$671K	Buy	3,083 +48	+2%	+$10.6K	0.4%	52
2025 Q4	$693K	Buy	3,035 +370	+14%	+$84.3K	0.41%	44
2025 Q3	$617K	Buy	2,665 +56	+2%	+$11.4K	0.39%	45
2025 Q2	$484K	Hold	2,609	–	–	0.33%	59
2025 Q1	$547K	Hold	2,609	–	–	0.37%	55
2024 Q4	$464K	Buy	+2,609	New	+$480K	0.32%	64

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Millstone Evans Group's ABBV Position: Q2 2026 in Review

Millstone Evans Group reduced its AbbVie (ABBV) stake by 19% in Q2 2026, selling an estimated $126K and leaving 2,498 shares worth $629K. The position accounts for 0.34% of the portfolio, ranked #51.

Millstone Evans Group first reported a position in ABBV in Q4 2024 and has held it in 7 quarters since. The position peaked at $693K in Q4 2025. 3,690 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Millstone Evans Group held 2,498 shares of AbbVie worth $629K as of Q2 2026.
Millstone Evans Group sold 585 AbbVie shares in Q2 2026, an estimated $126K.
AbbVie made up 0.34% of Millstone Evans Group's portfolio in Q2 2026, its #51 holding.
Millstone Evans Group first reported a position in AbbVie in Q4 2024 and has held it in 7 quarters since.
Millstone Evans Group's AbbVie position peaked at $693K in Q4 2025.
3,690 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Millstone Evans Group's 13F filing for Q2 2026, filed 11 Aug 2026.